Moderna's AI-designed personalized mRNA cancer therapy succeeds in Phase 3 trial
kimmonismus · x · 2026-08-19
Moderna and Merck's AI-assisted personalized mRNA cancer treatment has succeeded in a Phase 3 trial involving 1,137 patients.
Core Mechanism:
- Sequence patient tumors and healthy DNA, using AI to identify mutations most likely to trigger an immune response.
- Produce individualized mRNA treatments encoding up to 34 neoantigens per patient.
Clinical Data:
- Phase 2 showed 68.8% cancer-free survival at 5 years (vs. 49.1% with Keytruda alone).
- 49% lower risk of recurrence or death; 59% lower risk of distant metastasis or death.
- The larger Phase 3 trial has now confirmed these results.
Related event: Moderna-Merck AI Personalized mRNA Cancer Therapy Succeeds in Phase 3(3 posts)→
More from Apps
- Mureka V9.5 generates frighteningly realistic songs, fooling friends — LearnWithBishal · 2026-08-19
- Replit launches Free Mode powered by OpenAI's GPT-5.6 Luna — amasad · 2026-08-19
- Instinct AI demo handles mom's admin hell: tickets, waivers, and email cleanup — floguo · 2026-08-19
- Runway offers unlimited MiniMax H3 video generation for Max plan users — runwayml · 2026-08-19
- Peter Yang's Essay: Using AI to Help His Mom Fight Breast Cancer a Fourth Time — petergyang · 2026-08-19
- Canonical Lookalike Finder uses AI to discover talent and similar companies — ai · 2026-08-19